Drug profile · INN
pirtobrutinib
JAYPIRCA
pirtobrutinib (JAYPIRCA) is a tyrosine-protein kinase btk inhibitor. Route of administration: oral. Current US regulatory status: approved.
Drug details — pirtobrutinib
- US status
- approved
- Class
- Antineoplastic and immunomodulating agents (L01)
- Route
- ORAL
- Patents
- 0
- Programs
- 11
- Data quality
- 0.84
Quick answer
pirtobrutinib (JAYPIRCA) is a tyrosine-protein kinase btk inhibitor. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Tyrosine-protein kinase BTK inhibitor
Primary target: Tyrosine-protein kinase BTK
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| PMDA | approved | — |
| NMPA | clinical trials | — |
Recent coverage
Lilly to Spotlight Growing Hematology Portfolio at 2026 EHA Annual Meeting: Key Data and Strategic Implications
Lilly will present positive Phase 3 BRUIN CLL-322 results at the 2026 EHA Annual Meeting, comparing pirtobrutinib plus venetoclax and rituximab against venetoclax and rituximab. The presentation underscores Lilly's expanding hematology portfolio, bolstered by recent acquisitions of Ajax Therapeutics and Kelonia Therapeutics.
Eli Lilly's Foundayo (Orforglipron) Receives FDA Approval for Obesity Treatment as Company Reports Strong Q1 2026 Results
Eli Lilly announces FDA approval of Foundayo (orforglipron) for obesity treatment alongside positive Phase 3 results and raised full-year guidance in Q1 2026.
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is pirtobrutinib?
pirtobrutinib (JAYPIRCA) is a tyrosine-protein kinase btk inhibitor. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for pirtobrutinib?
JAYPIRCA is a marketed brand name for pirtobrutinib. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of pirtobrutinib?
pirtobrutinib has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.